FDA Should Create Separate Division To Review Drug-Induced Liver Toxicity – Consultant
This article was originally published in The Pink Sheet Daily
Executive Summary
The new division would allow for standardized evaluation of drugs with evidence of hepatoxicity, consultant Thomas Garvey says. He also recommends strengthening post-marketing reporting requirements.